Ignite Creation Date:
2024-05-06 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 2:13 PM
Study NCT ID:
NCT05038735
Status:
RECRUITING
Last Update Posted:
2024-05-07
First Post:
2021-09-01
Brief Title:
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive HR HER2-negative Advanced Breast Cancer After Treatment With a CDK46 Inhibitor and an Aromatase Inhibitor
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis